Sažetak | Objectives: The primary objective of this study was to evaluate the differences in plasminogen
activator inhibitor-1 (PAI-1) serum concentrations between hypertensive patients and healthy
controls and to assess the potential impact of obesity on PAI-levels within the hypertensive
population.
Subjects and methods: This cross-sectional study enrolled two groups, each consisting of 40
participants. One group consisted of patients diagnosed with hypertension, while the other one
consisted of age- and sex-matched healthy controls. Serum PAI-1 concentrations were
measured in a cohort of patients with arterial hypertension and age- and sex-matched healthy
controls. Participants were categorized into obese and non-obese groups based on body mass
index, with 30 kg/m2 set as the threshold. Clinical parameters including blood pressure, lipid
profile, and anthropometric data were collected. Correlation analysis between PAI-1 levels and
various clinical and laboratory parameters was performed using Pearson's correlation
coefficient.
Results: PAI-1 serum concentrations were significantly higher in patients with arterial
hypertension in comparison to healthy age- and sex-matched controls (4327.52 ± 1100.26
pg/mL vs. 2278.35 ± 1046.43 pg/mL, P < 0.001). Furthermore, PAI-1 serum concentrations
were significantly higher in obese hypertensive patients when compared to non-obese
hypertensive patients (4445.32 ± 1146.36 pg/mL vs. 4173.88 ± 1211.33 pg/mL, P = 0.031). A
significant positive correlation was found between PAI-1 levels and diastolic blood pressure (r
= 0.314, P = 0.004). No significant correlations were found between PAI-1 and age, BMI, total
cholesterol, LDL-C, HDL-C, or triglycerides, indicating that these factors may not directly
influence PAI-1 levels in hypertensive patients.
Conclusion: Overall, these findings suggest that PAI-1 may be a useful biomarker for
cardiovascular risk stratification in hypertensive patients. In addition, observations concerning
difference in PAI-1 depending on body mass index highlight the impact of obesity on
hypertensive pathology. |
Sažetak (hrvatski) | Ciljevi: Primarni cilj ove studije bio je procijeniti razlike u koncentracijama PAI-1 u serumu
između hipertenzivnih bolesnika i zdravih ispitanika te procijeniti potencijalni utjecaj pretilosti
na razine PAI-1 unutar hipertenzivne populacije.
Ispitanici i metode: Studija je uključivala dvije skupine, svaka od 40 sudionika. Jedna skupina
sastojala se od bolesnika s dijagnozom hipertenzije, dok je druga skupina uključivala dobno i
spolno usklađene zdrave ispitanike. Koncentracije PAI-1 u serumu mjerene su u kohorti
bolesnika s arterijskom hipertenzijom i dobno i spolno usklađenim zdravim ispitanicima.
Sudionici su kategorizirani u pretile i nepretile skupine prema indeksu tjelesne mase, s pragom
postavljenim na 30 kg/m². Prikupljeni su klinički parametri, uključujući krvni tlak, lipidni profil
i antropometrijske podatke. Korelacijska analiza između razina PAI-1 i različitih kliničkih i
laboratorijskih parametara provedena je korištenjem Pearsonovog korelacijskog koeficijenta.
Rezultati: Koncentracije PAI-1 u serumu bile su značajno više u bolesnika s arterijskom
hipertenzijom u usporedbi sa zdravim dobno i spolno usklađenim ispitanicima (4327,52 ±
1100,26 pg/mL naspram 2278,35 ± 1046,43 pg/mL, P < 0,001). Nadalje, koncentracije PAI-1
u serumu bile su značajno više u pretilih hipertenzivnih bolesnika u usporedbi s nepretilim
hipertenzivnim bolesnicima (4445,32 ± 1146,36 pg/mL naspram 4173,88 ± 1211,33 pg/mL, P
= 0,031). Pronađena je značajna pozitivna korelacija između razina PAI-1 i dijastoličkog
krvnog tlaka (r = 0,314, P = 0,004). Nisu pronađene značajne korelacije između PAI-1 i dobi,
BMI-a, ukupnog kolesterola, LDL-C-a, HDL-C-a ili triglicerida, što ukazuje na to da ovi faktori
možda ne utječu izravno na razine PAI-1 u hipertenzivnih bolesnika.
Zaključak: Ovi rezultati sugeriraju da PAI-1 može biti koristan biomarker za stratifikaciju
kardiovaskularnog rizika u hipertenzivnih bolesnika. Osim toga, zapažanja o razlikama u
razinama PAI-1 ovisno o indeksu tjelesne mase naglašavaju utjecaj pretilosti na patologiju
hipertenzije. |